Multimodal Management of stage 2 and 3 extraocular retinoblastoma An Interventional pilot study

Multimodal Management of stage II and III extraocular retinoblastoma : An Interventional pilot study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066837

Enrollment

Registered

2024-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C692- Malignant neoplasm of retina Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Multimodal management: 4 cycles of adjuvant Chemotherapy with Vincristine (1.5 mg/m2 on D0, D7, D14) , cyclophosphamide(1950 mg/m2 on D1, D2), Cisplatin (105 mg/m2 on D0) and Etoposide

Eligibility

Inclusion criteria

Inclusion criteria: Those fulfilling the criteria for IRSS stage II and III of extraocular retinoblastoma defined previously will be included in the study.

Exclusion criteria

Exclusion criteria: Pre-existing renal disease Pre-existing Hearing impairment Relapsed extraocular retinoblastoma

Design outcomes

Primary

Measure	Time frame
To estimate the Disease free survival (DFS) at 1 year after multimodal management in children less than 18 years diagnosed with stage II and III extraocular retinoblastomaTimepoint: 12 months after treatment completion	—

Secondary

Measure	Time frame
To study the adverse effects using CTCAE criteria in children less than 18 years diagnosed with stage II & III extraocular retinoblastoma To study the variability in interpretation of PET/CT & MRI in management of stage II & III extraocular retinoblastoma in children less than 18 years To evaluate ototoxicity associated with this regimen in children less than 18 years diagnosed with stage II & III extraocular retinoblastomaTimepoint: 1 year	—

Measure

Time frame

To study the adverse effects using CTCAE criteria in children less than 18 years diagnosed with stage II & III extraocular retinoblastoma To study the variability in interpretation of PET/CT & MRI in management of stage II & III extraocular retinoblastoma in children less than 18 years To evaluate ototoxicity associated with this regimen in children less than 18 years diagnosed with stage II & III extraocular retinoblastomaTimepoint: 1 year

—

Countries

India

Contacts

Public ContactShivani Deep Singh

All India Institute of Medical Sciences, New Delhi

drrachnaseth1967@gmail.com9971188687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026